Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.31 |
| ▸ | FAAH | O00519 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23005228 | 0.88 | SIGMAR1 (0.39) | KMT2AMEN1SIGMAR1MAPT | |
| SCHEMBL23005212 | 0.86 | MMP2 (0.35) | KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL23005135 | 0.86 | KMT2A (0.34) | KMT2AMAPTFAAH | |
| SCHEMBL23005201 | 0.85 | KMT2A (0.44) | KMT2AMAPT | |
| SCHEMBL23005219 | 0.84 | KMT2A (0.36) | KMT2AMAPT | |
| SCHEMBL23005234 | 0.78 | KMT2A (0.36) | KMT2AMAPT | |
| SCHEMBL23005167 | 0.72 | — | — | |
| SCHEMBL14997680 | 0.72 | MEN1 (0.32) | KMT2AMEN1ALDH1A1SIGMAR1POLB | |
| SCHEMBL23005258 | 0.70 | HTR2A (0.41) | KMT2AMEN1ALDH1A1SIGMAR1MAPT | |
| SCHEMBL28896083 | 0.68 | SIGMAR1 (0.45) | KMT2AMEN1ALDH1A1SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | DREXEL UNIVERSITY | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174275-B2 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | HSD17B7, CYP4A22, PPOX | KMT2A 2539/4885MEN1 2924/4885ALDH1A1 941/4885 |
| US-20210054003-A1 | Methods for the preparation of cyclopentaoxasilinones and cyclopentaoxaborininones and their use | HSD17B7, CYP4A22, PPOX | KMT2A 2539/4885MEN1 2924/4885ALDH1A1 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.